Spots Global Cancer Trial Database for bibf 1120
Every month we try and update this database with for bibf 1120 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies | NCT02182245 | Genital Neoplas... | BIBF 1120 Paclitaxel Carboplatin | 18 Years - | Boehringer Ingelheim | |
| Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours. | NCT00998296 | Neoplasms | BIBW 2992 BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. | NCT01346540 | Carcinoma, Non-... | BIBF 1120 Placebo | 18 Years - | Boehringer Ingelheim | |
| A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer | NCT02182232 | Carcinoma, Non-... | BIBF 1120 Paclitaxel Carboplatin | 18 Years - | Boehringer Ingelheim | |
| A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120 | NCT00715403 | Neoplasms | BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | NCT01004003 | Carcinoma, Hepa... | Sorafenib BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1) | NCT01684111 | Carcinoma, Non-... | BIBF 1120 Vinorelbine | 71 Years - | Aktion Bronchialkarzinom e.V. | |
| BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer | NCT00904839 | Colorectal Neop... | BIBF 1120 BIBF 1120 mFolfox Bevacizumab mFolfox 6 bevacizumab | 18 Years - | Boehringer Ingelheim | |
| Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. | NCT01024920 | Carcinoma, Rena... | BIBF 1120 sunitinib | 18 Years - | Boehringer Ingelheim | |
| NOA-12: BIBF1120 and R-RT in Glioblastoma | NCT01666600 | Glioblastoma Mu... | BIBF 1120 radiotherapy | 18 Years - | University Hospital Heidelberg | |
| Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer | NCT01610869 | Ovarian Cancer Fallopian Tube ... | BIBF 1120 | 18 Years - | University College, London | |
| Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | NCT01485874 | Ovarian Cancer | Doxil (Pegylate... BIBF 1120 | 18 Years - | Hoosier Cancer Research Network | |
| A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120 | NCT00715403 | Neoplasms | BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2) | NCT01683682 | Carcinoma, Non-... | BIBF 1120 Vinorelbine Carboplatin | 71 Years - | Aktion Bronchialkarzinom e.V. | |
| LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer | NCT01015118 | Ovarian Neoplas... Peritoneal Neop... | Placebo Paclitaxel BIBF 1120 Carboplatin Paclitaxel Carboplatin | 18 Years - | Boehringer Ingelheim | |
| BIBF 1120 for Recurrent High-Grade Gliomas | NCT01380782 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | BIBF 1120 | 18 Years - | Dana-Farber Cancer Institute | |
| Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer | NCT01610869 | Ovarian Cancer Fallopian Tube ... | BIBF 1120 | 18 Years - | University College, London | |
| Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors | NCT00730821 | Neoplasms | BIBW 2992 BIBF 1120 | 18 Years - 75 Years | Boehringer Ingelheim | |
| An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours | NCT02182206 | Tumors | BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer | NCT01441297 | Small Cell Lung... Small Cell Lung... | BIBF 1120 | 18 Years - | National Cancer Center, Korea | |
| A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. | NCT01346540 | Carcinoma, Non-... | BIBF 1120 Placebo | 18 Years - | Boehringer Ingelheim | |
| An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1) | NCT01684111 | Carcinoma, Non-... | BIBF 1120 Vinorelbine | 71 Years - | Aktion Bronchialkarzinom e.V. | |
| To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours | NCT01951846 | Malignant Solid... | BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors | NCT01022853 | Neoplasms | BI 6727 BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | NCT01669798 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | BIBF 1120 | 18 Years - | Duke University | |
| Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. | NCT01024920 | Carcinoma, Rena... | BIBF 1120 sunitinib | 18 Years - | Boehringer Ingelheim | |
| Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer | NCT01610869 | Ovarian Cancer Fallopian Tube ... | BIBF 1120 | 18 Years - | University College, London | |
| BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer | NCT00904839 | Colorectal Neop... | BIBF 1120 BIBF 1120 mFolfox Bevacizumab mFolfox 6 bevacizumab | 18 Years - | Boehringer Ingelheim | |
| A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours | NCT02182128 | Tumors | BIBF 1120 | 20 Years - | Boehringer Ingelheim | |
| An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours | NCT02182206 | Tumors | BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours | NCT02182128 | Tumors | BIBF 1120 | 20 Years - | Boehringer Ingelheim | |
| A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer | NCT00706628 | Prostatic Neopl... | BIBF 1120 BIBW 2992 Sequential BIBF... | 18 Years - | Boehringer Ingelheim | |
| Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours. | NCT00998296 | Neoplasms | BIBW 2992 BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors | NCT00730821 | Neoplasms | BIBW 2992 BIBF 1120 | 18 Years - 75 Years | Boehringer Ingelheim |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
